Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer

Lawson Health Research Institute

Status: Completed

Conditions: Prostate Cancer; Bone Loss

Study type: Observational

Funder types: Other

Identifiers

NCT00199537

R-05-055

UWO ADF SG06-02

Lawson IRF-071-04

Details and patient eligibility

About

Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.

Enrollment: 25 patients

Sex: Male

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men
• Age of 40 years or greater
• Diagnosis of advanced prostate cancer (ie: prostate-specific antigen [PSA] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone [LHRH] therapy)
• Willing and able to consent

Exclusion criteria

• Metastatic disease to bone
• Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant)
• Renal failure (serum creatinine > 200 umol/L)
• Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis)
• Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty)
• Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial
• Gastrointestinal (GI) pathology (eg. malabsorption syndrome)
• Parathyroid disease